Lilly’s Eczema Contender Promising, But Needs Head-To-Head Data To Dent Dupixent Dominance
Also Vital For Partners Almirall
Topline results suggest lebrikizumab could outshine Sanofi’s Dupixent on safety and itch reduction in atopic eczema, but a direct comparison study is likely required to drive the message home.
